Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Oklahoma Medical Research Foundation

Seattle Genetics, Inc.

Bayer As

Lars Linden

Andreas Wilmen

Christoph Freiberg

Simone Greven

Mark Trautwein

Joachim Schuhmacher

Hans-Georg Lerchen

Alan Cuthbertson

Hanna Tinel

Karl-Heinz Thierauch

Beatrix Stelte-Ludwig

Jan Tebbe

Axel Harrenga

Christiane Otto

Christoph Mahlert

Iring Heisler

Sherif El Sheikh

Frank Dittmer

Charlotte Christine Kopitz

Sven Golfier

Ricarda Finnern

Xiao-Yan Zhao

Jörg Willuda

Ji-Yun Kim

Ulrich Haupts

Sandra Bruder

Hannah Jöriβen

Heike Petrul

Sandra Borkowski

Gabriele Leder

Anke Mayer-bartschmid

Xinquan Wang

Subramanian Yegneswaran

Karin Regnstrom

Kirsten Leineweber

Ursula Egner

Rudolf Beier

Juergen Franz

Yong-Jiang Cao

The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-targeting moiety targeting HER2; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising admistration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided.

Radio-pharmaceutical complexes

Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.

Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof

The present invention is directed to the neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody of the invention blocks prolactin receptor-mediated signalling.

Neutralizing prolactin receptor antibody Mat3 and its therapeutic use

The present invention provides Relaxin fusion polypeptides A-L-B with a non-wild type array of the Relaxin A-chain and Relaxin B-chain, wherein the A- and B-chains are connected by a linker peptide. The invention further provides Relaxin fusion polypeptides with extended half-life. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, pharmaceutical compositions and medical use of such fusion polypeptides.

Relaxin fusion polypeptides and uses thereof

The neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody blocks prolactin receptor-mediated signalling.

The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practiced as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Binder-drug conjugates (ADCs) and use thereof

Growing community of inventors

Düsseldorf, Germany

Lars Linden